Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic mesenchymal stromal cells for emphysema progression after staged lung volume reduction surgery
NL-OMON48907Phase 2Recruiting
- Sponsor
- Longfonds
- Start
- Jun 2018
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of allogeneic bone marrow-derived mesenchymal stromal cells in emphysema and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Longfonds. Primary endpoints: CD31 expression on pulmonary microvascular endothelial cells after 4 weeks and Long-term change in carbon monoxide diffusion capacity. Started Jun 2018; status: recruiting.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
emphysemachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON48907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48907.